Metabolic biomarkers from blood and tumor tissue for early detection and prognosis of gastric cancer
Official title: Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Gastric：MetBio-GC
Run by Shanghai Minimally Invasive Surgery Center · NCT07076979 · Data updated 2026-11-12
This project will test whether metabolic markers measured in blood and tumor tissue can help detect gastric cancer earlier and predict prognosis and recurrence for adults with gastric adenocarcinoma.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 250 (estimated) |
| Sponsor | Shanghai Minimally Invasive Surgery Center Academic / other |
| Locations | 1 site (Shanghai) |
| Status | Recruiting |
| Started | June 15, 2025 |
| Main results expected | July 1, 2028 |
| Study ends | July 1, 2030 |
| Registry record updated | July 22, 2025 |
| Trial ID | NCT07076979 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults (≥18) with histopathologically confirmed gastric adenocarcinoma who have not received prior anti‑tumor treatment, have ECOG performance status ≤1, and can provide required tumor tissue and peripheral blood samples, as well as consenting healthy adult controls.
✕Probably not a fit
Patients who have had prior cancer therapy, have hereditary cancer syndromes, lack adequate tissue or blood samples, have poor performance status (ECOG >1), or have non‑adenocarcinoma gastric tumors are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective observational project enrolling treatment‑naive adults with histologically confirmed gastric adenocarcinoma and healthy control volunteers at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. Researchers will collect peripheral blood and primary tumor tissue and apply metabolomics to build a gastric cancer–specific metabolite database. The study will search for metabolic signatures associated with early diagnosis, prognosis, recurrence and metastasis, then validate candidate biomarkers within the cohort. The goal is to develop a safe, convenient, and sensitive approach to support early screening and prognostic prediction.
Why it matters
Potential benefit: If successful, the biomarkers could enable earlier, less invasive detection of gastric cancer and more accurate prediction of recurrence to guide treatment and follow‑up.
How similar studies have gone: Previous metabolomics studies have identified promising metabolic biomarkers for gastric cancer, but few have been validated prospectively in large clinical cohorts and clinical use remains limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * \*\*Healthy Controls:\*\* 1. Age \> 18 years; 2. Signed informed consent and willingness to participate in the project. \*\*Gastric Cancer:\*\* 1. Age ≥ 18 years; 2. Performance status (ECOG) score ≤ 1; 3. Histopathologically confirmed gastric adenocarcinoma; 4. No family history of hereditary cancer; 5. No prior anti-tumor treatment; 6. Availability of primary tumor tissue from surgery or biopsy that meets submission requirements; 7. Availability of peripheral blood samples that meet submission requirements; 8. Willingness and ability to sign the informed consent form to participate in the study. Exclusion Criteria: * \*\*Healthy Controls:\*\* 1. Individuals at high risk for hereditary colorectal adenocarcinoma, including family members of the following diseases: family history of gastrointestinal tumors, familial adenomatous polyposis (FAP), hereditary nonpolyposis colorectal cancer (HNPCC/LS), and Peutz-Jeghers syndrome (P-J syndrome); 2. History of chronic metabolic or inflammatory diseases that are difficult to control, such as hypertension, diabetes, chronic viral hepatitis, and inflammatory bowel disease; 3. Known history of other malignancies that have progressed or required treatment within the past 5 years, except for skin basal cell carcinoma and squamous cell carcinoma that have been cured; 4. History of oral or intravenous use of broad-spectrum antibiotics and probiotics within the past month; 5. Regular use of immunosuppressive drugs within the past 6 months; 6. Long-term use of other medications that may affect metabolism, such as hormones; 7. Inability or unwillingness to cooperate with follow-up visits and related examinations; 8. Inability to eat normally or requiring medications or enemas for bowel movements; 9. Presence of psychiatric disorders or other severe cardiovascular diseases; 10. Pregnant, breastfeeding, or planning to become pregnant within the next year; 11. Currently participating in an interventional clinical study or receiving study treatment that may influence the patient's treatment decision. \*\*Gastric Cancer:\*\* 1. Currently participating in an interventional clinical study or receiving study treatment that may influence the patient's treatment decision; 2. Known history of other malignancies that have progressed or required treatment within the past 5 years, except for skin basal cell carcinoma and squamous cell carcinoma that have been cured; 3. History of chronic metabolic or inflammatory diseases that are difficult to control, such as hypertension, diabetes, chronic viral hepatitis, and inflammatory bowel disease; 4. Presence of poorly controlled chronic comorbidities that may affect prognosis; 5. Presence of psychiatric disorders or other severe cardiovascular diseases; 6. Pregnant, breastfeeding, or planning to become pregnant within the next year; 7. Long-term use of medications that may affect metabolism, such as hormones, immunosuppressants, antibiotics, etc.; 8. Any severe and/or uncontrolled medical conditions, as judged by the investigator, that may affect the patient's ability to participate in the study or interfere with study results.
Where it's running
-
Ruijin hospital Shanghai Jiaotong University, School of Medicine , Shanghai, Shanghai 200025
Shanghai, China Recruiting
Study contacts
- Study coordinator: Jing Sun
- Email: sj117788@rjh.com.cn
- Phone: +86-13524284622
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer
This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer
This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ABBV-253 in adults with advanced solid tumors
This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.